Mindray(SZ:300760) Cai Jing Wang·2025-04-29 10:55Core Viewpoint - Mindray Medical (300760.SZ) reported a revenue of 36.726 billion RMB for 2024, marking a year-on-year growth of 5.14%, and a net profit attributable to shareholders of 11.668 billion RMB, with a growth of 0.74% year-on-year, maintaining seven consecutive years of revenue and net profit growth since its A-share listing in 2018 [1][2] Financial Performance - The company plans to distribute a cash dividend of 5.60 RMB per 10 shares, totaling 679 million RMB for 2024, leading to a cumulative cash dividend of 7.602 billion RMB for the year, with a cash dividend ratio of 65.15% [1][2] - Since its listing, Mindray has distributed over 34 billion RMB in dividends and has not engaged in refinancing, with a cash dividend ratio of 60.72% for 2023 [2] - The company has outlined a shareholder return plan for the next three years (2025-2027), committing to at least one profit distribution annually, with cash distributions not less than 65% of the distributable profits [2] Business Segments Performance - The Life Information and Support segment generated 13.557 billion RMB in revenue, with the minimally invasive surgery business growing over 30% year-on-year [3] - The In Vitro Diagnostics segment achieved 13.765 billion RMB in revenue, a year-on-year increase of 10.82%, becoming the largest business segment [3] - The Medical Imaging segment reported 7.498 billion RMB in revenue, with a growth of 6.6% year-on-year, and the high-end ultrasound system Resona A20 generated over 400 million RMB in its first year [3] R&D and Innovation - Mindray's R&D investment reached 4.008 billion RMB in 2024, accounting for 10.91% of total revenue, with a total of 11,773 patent applications filed [3] Market Environment and Growth Prospects - The domestic procurement environment is recovering, and the company anticipates significant growth in international markets, with a 21.28% increase in international business revenue, now accounting for approximately 45% of total revenue [5][6] - The company is adapting to challenges such as tariffs and is confident in maintaining supply chain stability while aiming to enter the top 20 global medical device companies [7]